Anzeige
Mehr »
Mittwoch, 11.02.2026 - Börsentäglich über 12.000 News
Breaking News: Pacifica meldet neue hochgradige Entdeckung und genau deshalb kann der Markt das nicht ignorieren
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
789 Leser
Artikel bewerten:
(2)

ADM Tronics Unlimited, Inc.: ADM Tronics Reports Fiscal Year 2022

NORTHVALE, NJ / ACCESSWIRE / July 8, 2022 / ADM Tronics Unlimited, Inc. (OTCQB:ADMT), a technology-based developer and manufacturer of innovative technologies, products and proprietary medical devices, today announced results for fiscal year ended March 31, 2022.

"Our research and development of the Vet-Sonotron non-invasive veterinary therapy technology continues to be our focus," stated Andre' DiMino, President of ADMT. "Although the supply chain shortages and disruptions continue to present hurdles, not only to our Vet-Sonotron efforts, but in all areas of our activities, we believe Vet-Sonotron production units should available soon."

Mr. DiMino continues, "The commercialization of the Vet-Sonotron will be a major milestone for ADMT. It will also be a prelude to further development of the technology for the Sonotron Mark 2, human medical device which, when completed, will be submitted to the FDA for 510K clearance. We are confident that the Vet-Sonotron and Sonotron Mark 2 will provide our company with opportunities for significant growth."

Revenues for the year ended March 31, 2022, were $3,206,594 compared to $3,090,631 for the previous year, an increase of approximately 4%. Gross profit for the fiscal year was $1,248,638 or approximately 39% as compared to $1,161,842 or approximately 38% for the previous fiscal year. Due primarily to certain no-recurring write-offs, operating expenses for the fiscal year increased to $2,377,952 as compared to $1,842,320 for the previous fiscal year. R&D expenses were $615,926 as compared to $655,962 for the previous fiscal year. Complete financial results are available in the Company's Annual Report on Form 10K at www.sec.gov.

Financial Highlights

Fiscal Year Ended Fiscal Year Ended
March 31, 2022 March 31, 2021
Net revenues
$3,206,594 $3,090,631
Cost of sales
$1,957,956 $1,928,789
Gross Profit
$1,248,638 $1,161,842
Operating expenses
$2,377,952 $1,842,320
Loss from operations
$(1,129,314) $(680,478)
Total other income
$681,233 $14,202
Total benefit (provisions) from income taxes
$936,182 $(68,000)
Net (loss)
$1,384,263 $(598,276)
Earnings per common share
$(0.02) $(0.01)
Weighted average shares of common stock outstanding - diluted
67,588,492 67,588,492


About ADMT

ADMT is a diversified, technology-based developer and manufacturer of innovative technologies, products and proprietary medical devices. Its core competency is its ability to conceptualize a technology, bring it through development, into manufacturing and commercialization, all in-house. ADMT has three areas of activity: Proprietary Electronic Medical Devices; Design, Engineering, Regulatory and Manufacturing Services and Eco-Friendly, Water-Based Formulations. The Company's headquarters, laboratories, FDA-Registered medical device and manufacturing operations are located in Northvale, NJ. ADMT's multi-disciplinary team of engineers, researchers and technologists utilize advanced technology infrastructure, for the research, development and commercialization of diversified technologies. Additional information is at admtronics.com. To receive email updates directly from the Company, fill in the form at the bottom of this page: https://admtronics.com/investor-relations/

Except for historical information contained herein, the matters set forth in this news release are "forward-looking" statements (as defined in the Private Securities Litigation Reform Act of 1995), including statements regarding future revenue growth and performance. Although ADMT believes the expectations reflected in such forward-looking statements are based upon reasonable assumptions, there can be no assurance that its expectations will be realized. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from expectations. Factors that could contribute to such differences include those described from time to time in ADMT's filings with the SEC, news releases and other communications. The Company assumes no obligation to update the information contained in this news release.

Contact:
Andre' DiMino
201-767-6040
andre@admtronics.com

SOURCE: ADM Tronics Unlimited, Inc.



View source version on accesswire.com:
https://www.accesswire.com/708097/ADM-Tronics-Reports-Fiscal-Year-2022

© 2022 ACCESS Newswire
Favoritenwechsel
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.